Trial Profile
A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 23 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.